Bellicum Pharmaceuticals has switched up its deal with Ariad Pharmaceuticals, agreeing to hand over $50 million for a no-strings-attached license to some cell-signaling technology.
Unilife, the injectable technology provider, has inked a deal with Sanofi to be the French drugmaker's sole provider of cartridge-based wearable injectors for the next 15 years.
Kidney drug developer Rockwell Medical picked up a big co-sign from a leader in the space, signing a deal with Baxter International that will help pay the way for its late-stage iron-delivery treatment.
Boehringer Ingelheim envisions some day selling day a smart inhaler that can tell patients when its medication is running low and remind them if they missed a prescheduled dose.
Aerocrine has partnered with Microsoft in a pilot project to send data from nitric oxide monitoring devices to the cloud for analysis.
U.K. drug development outfit Ergomed has come out the other end of its London IPO, touting a range of R&D partnerships that give it a chance to share the rewards of its clients' work.
The recently IPO'd Catalent has signed a deal with biotech Cingulate Therapeutics to help develop a duo of candidates for ADHD, tapping its expertise in crafting controlled-release tablets.
Germany's Evotec has joined a trio of research projects focused on multiple sclerosis, contributing its developmental know-how to some early-stage R&D.
Pharmacyclics and Servier are quietly walking away from a 5-year collaboration on a new cancer treatment, leaving the former company to go it alone on mid-stage oral drug with an uncertain future.
Apple's HealthKit data-sharing platform for mobile health apps has been pulled from the iPhone 6's operating system after an upgrade to iOS 8 disrupted cellular service, resulting in a bucketful of delayed app launches or upgrades, to the benefit of competitors.